Sort   by:  
 Page size 
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

Background

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).

Methods

We randomly assigned inpa...
S-EPMC7727327 | biostudies-literature
UnknownBoosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

Background

Current clinical guidelines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among their recommended and alternative first-line antiretroviral regimens. However, thes...
S-EPMC4447777 | biostudies-literature
UnknownGlobal Burden of Cardiovascular Diseases and Risks, 1990-2022.
Not available
S-EPMC7615984 | biostudies-literature
Sort   by:  
 Page size